logo-loader
viewKazia Therapeutics Ltd

Kazia Therapeutics moves into operational phase of pivotal study for paxalisib in glioblastoma

Kazia Therapeutics Ltd's (ASX:KZA) James Garner speaks to Proactive's Andrew Scott soon after announcing they've executed a definitive agreement with the Global Coalition for Adaptive Research (GCAR) to begin participation in the GBM AGILE pivotal study in glioblastoma. The study is set to open a new arm with Kazia’s investigational new drug, paxalisib, and will now move into an operational phase with recruitment of patients to the paxalisib arm expected to begin in the first quarter of 2021.

Quick facts: Kazia Therapeutics Ltd

Price: 1.355 AUD

ASX:KZA
Market: ASX
Market Cap: $128.21 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Kintara Therapeutics and Kazia Therapeutics begin trial to treat deadly...

Kintara Therapeutics Inc (NASDAQ:KTRA) CEO Saiid Zarrabian tells Proactive that its drug VAL-083 has been activated for an adaptive platform recurrent glioblastoma (GBM) trial. Zarrabian says Kintara, along with Kazia Therapeutics Limited (ASX:KZA) (NASDAQ:KZIA) and its drug paxalisib, will...

1 week, 4 days ago

2 min read